Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings

Joanne M Langley, Veronique Bianco, Joseph B Domachowske, Shabir A Madhi, Sonia K Stoszek, Khalequ Zaman, Agustin Bueso, Ana Ceballos, Luis Cousin, Ulises D'Andrea, Ilse Dieussaert, Janet A Englund, Sanjay Gandhi, Olivier Gruselle, Gerco Haars, Lisa Jose, Nicola P Klein, Amanda Leach, Koen Maleux, Thi Lien Anh Nguyen, Thanyawee Puthanakit, Peter Silas, Auchara Tangsathapornpong, Jamaree Teeratakulpisarn, Timo Vesikari, Rachel A Cohen, Joanne M Langley, Veronique Bianco, Joseph B Domachowske, Shabir A Madhi, Sonia K Stoszek, Khalequ Zaman, Agustin Bueso, Ana Ceballos, Luis Cousin, Ulises D'Andrea, Ilse Dieussaert, Janet A Englund, Sanjay Gandhi, Olivier Gruselle, Gerco Haars, Lisa Jose, Nicola P Klein, Amanda Leach, Koen Maleux, Thi Lien Anh Nguyen, Thanyawee Puthanakit, Peter Silas, Auchara Tangsathapornpong, Jamaree Teeratakulpisarn, Timo Vesikari, Rachel A Cohen

Abstract

Background: The true burden of lower respiratory tract infections (LRTIs) due to respiratory syncytial virus (RSV) remains unclear. This study aimed to provide more robust, multinational data on RSV-LRTI incidence and burden in the first 2 years of life.

Methods: This prospective, observational cohort study was conducted in Argentina, Bangladesh, Canada, Finland, Honduras, South Africa, Thailand, and United States. Children were followed for 24 months from birth. Suspected LRTIs were detected via active (through regular contacts) and passive surveillance. RSV and other viruses were detected from nasopharyngeal swabs using PCR-based methods.

Results: Of 2401 children, 206 (8.6%) had 227 episodes of RSV-LRTI. Incidence rates (IRs) of first episode of RSV-LRTI were 7.35 (95% confidence interval [CI], 5.88-9.08), 5.50 (95% CI, 4.21-7.07), and 2.87 (95% CI, 2.18-3.70) cases/100 person-years in children aged 0-5, 6-11, and 12-23 months. IRs for RSV-LRTI, severe RSV-LRTI, and RSV hospitalization tended to be higher among 0-5 month olds and in lower-income settings. RSV was detected for 40% of LRTIs in 0-2 month olds and for approximately 20% of LRTIs in older children. Other viruses were codetected in 29.2% of RSV-positive nasopharyngeal swabs.

Conclusions: A substantial burden of RSV-LRTI was observed across diverse settings, impacting the youngest infants the most. Clinical Trials Registration. NCT01995175.

Keywords: burden of disease; epidemiology; incidence; infants; respiratory syncytial virus; respiratory tract infections; young children.

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Figures

Graphical Abstract
Graphical Abstract
Figure 1.
Figure 1.
Participant flowchart and local RSV transmission period. The RSV transmission period in each country was defined based on the actual observed RSV season during the period of surveillance for each country. For countries such as Canada, the Unites States, and Finland, which had well-established RSV surveillance systems in place near the study sites, the actual reported RSV season start and stop dates (by month) were used to define the RSV transmission period. If the RSV season was longer in 1 year than the other and >5% of children for that country were exposed to the longer season, then the longer season was considered. In countries without a robust RSV surveillance system, the RSV transmission period was established through the identification of at least 1 RSV case in each month defined as being within the RSV season. In order for the month to be counted as within the RSV season for that country, the month had to be adjacent to at least 1 other month that similarly met the definition for being within the RSV season. Abbreviation: RSV, respiratory syncytial virus.
Figure 2.
Figure 2.
Incidence rate of first episode of RSV-LRTI (A), severe RSV-LRTI (B), and RSV hospitalization (C) by age group, overall, and by country. Error bars represent 95% CIs. Abbreviations: CI, confidence interval; IR, incidence rate (cases/100 person-years); LRTI, lower respiratory tract infection; RSV, respiratory syncytial virus.
Figure 3.
Figure 3.
Virus codetection in laboratory-confirmed RSV-LRTI cases (left) and according to RSV subtype (right), by age group, overall, and by country. Abbreviations: LRTI, lower respiratory tract infection; RSV, respiratory syncytial virus. aNo LRTIs were observed in these age groups.

References

    1. GBD 2017 Causes of Death Collaborators . Global, regional, and national age-sex-specific mortality for 2017; 282, causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet 2018; 392:1736–88.
    1. World Health Organization . The global health observatory: causes of child death. . Accessed 21 July 2021.
    1. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017; 390:946–58.
    1. Stein RT, Bont LJ, Zar H, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol 2017; 52:556–69.
    1. Pneumonia Etiology Research for Child Health (PERCH) Study Group . Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet 2019; 394:757–79.
    1. Shi T, Denouel A, Tietjen AK, et al. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis 2020; 222:S577–83.
    1. Shi T, Vennard S, Mahdy S, Nair H. Risk Factors for Poor Outcome or Death in Young Children With Respiratory Syncytial Virus–Associated Acute Lower Respiratory Tract Infection: A Systematic Review and Meta-Analysis. J Infect Dis 2022; 226:S10–6.
    1. Tin Tin Htar M, Yerramalla MS, Moïsi JC, Swerdlow DL. The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis. Epidemiol Infect 2020; 148:e48.
    1. Domachowske J, Halczyn J, Bonville CA. Preventing pediatric respiratory syncytial virus infection. Pediatr Ann 2018; 47:e371–6.
    1. Pangesti KNA, El Ghany MA, Kesson AM, Hill-Cawthorne GA. Respiratory syncytial virus in the Western Pacific region: a systematic review and meta-analysis. J Glob Health 2019; 9:020431.
    1. Suleiman-Martos N, Caballero-Vázquez A, Gómez-Urquiza JL, Albendín-García L, Romero-Béjar JL, Cañadas-De la Fuente GA. Prevalence and risk factors of respiratory syncytial virus in children under 5 years of age in the WHO European region: a systematic review and meta-analysis. J Pers Med 2021; 11:416.
    1. Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23–24 March 2015. Vaccine 2016; 34:190–7.
    1. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137:865–70.
    1. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003; 88:1065–9.
    1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588–98.
    1. Holman RC, Curns AT, Cheek JE, et al. Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population. Pediatrics 2004; 114:e437–44.
    1. Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004; 113:1758–64.
    1. Vicente D, Montes M, Cilla G, Perez-Yarza EG, Perez-Trallero E. Hospitalization for respiratory syncytial virus in the paediatric population in Spain. Epidemiol Infect 2003; 131:867–72.
    1. Bennett S, Woods T, Liyanage WM, Smith DL. A simplified general method for cluster-sample surveys of health in developing countries. World Health Stat Q 1991; 44:98–106.
    1. Nokes DJ, Okiro EA, Ngama M, et al. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya. Clin Infect Dis 2008; 46:50–7.
    1. Li Y, Reeves RM, Wang X, et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Glob Health 2019; 7:e1031–45.
    1. Staadegaard L, Caini S, Wangchuk S, et al. Defining the seasonality of respiratory syncytial virus around the world: national and subnational surveillance data from 12 countries. Influenza Other Respir Viruses 2021; 15:732–41.
    1. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee . Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134:415–20.
    1. European Medicines Agency . Synagis: summary of the European public assessment report. . Accessed 23 September 2021.
    1. Ginsburg AS, Srikantiah P. Respiratory syncytial virus: promising progress against a leading cause of pneumonia. Lancet Glob Health 2021; 9:e1644–5.
    1. Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020; 383:415–25.
    1. Drysdale SB, Barr RS, Rollier CS, Green CA, Pollard AJ, Sande CJ. Priorities for developing respiratory syncytial virus vaccines in different target populations. Sci Transl Med 2020; 12:eaax2466.
    1. Giersing BK, Karron RA, Vekemans J, Kaslow DC, Moorthy VS. Meeting report: WHO consultation on respiratory syncytial virus (RSV) vaccine development. Geneva: 25–26 April 2016. Vaccine 2019; 37:7355–62.
    1. PATH . RSV vaccine and mAb snapshot. . Accessed 23 September 2021.
    1. Calvo C, García-García ML, Pozo F, et al. Respiratory syncytial virus coinfections with rhinovirus and human bocavirus in hospitalized children. Medicine 2015; 94:e1788.
    1. da Silva ER, Pitrez MCP, Arruda E, et al. Severe lower respiratory tract infection in infants and toddlers from a non-affluent population: viral etiology and co-detection as risk factors. BMC Infect Dis 2013; 13:41.
    1. Mazur NI, Bont L, Cohen AL, et al. Severity of respiratory syncytial virus lower respiratory tract infection with viral coinfection in HIV-uninfected children. Clin Infect Dis 2017; 64:443–50.
    1. Li Y, Pillai P, Miyake F, Nair H. The role of viral co-infections in the severity of acute respiratory infections among children infected with respiratory syncytial virus (RSV): a systematic review and meta-analysis. J Glob Health 2020; 10:010426.
    1. Tempia S, Walaza S, Bhiman JN, et al. Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa. January to October 2020. Euro Surveill 2021; 26:2001600.
    1. van Summeren J, Meijer A, Aspelund G, et al. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? Euro Surveill 2021; 26:2100639.
    1. Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Natl Acad Sci USA 2020; 117:30547–53.
    1. Ujiie M, Tsuzuki S, Nakamoto T, Iwamoto N. Resurgence of respiratory syncytial virus infections during COVID-19 pandemic, Tokyo, Japan. Emerg Infect Dis 2021; 27:2969–70.
    1. von Hammerstein AL, Aebi C, Barbey F, et al. Interseasonal RSV infections in Switzerland—rapid establishment of a clinician-led national reporting system (RSV EpiCH). Swiss Med Wkly 2021; 151:w30057.
    1. Limb M. RSV: The year the respiratory infection “took its gloves off”. BMJ 2021; 374:n2078.
    1. Eden JS, Sikazwe C, Xie R, et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat Commun 2022; 13:2884.
    1. Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics 2021; 148:e2021052089.
    1. Centers for Disease Control and Prevention, Health Alert Network . Increased interseasonal respiratory syncytial virus (RSV) activity in parts of the Southern United States. . Accessed 23 September 2021.
    1. Romanello M, McGushin A, Di Napoli C, et al. The 2021 report of the lancet countdown on health and climate change: code red for a healthy future. Lancet 2021; 398:1619–62.
    1. Betran AP, Ye J, Moller AB, Souza JP, Zhang J. Trends and projections of caesarean section rates: global and regional estimates. BMJ Glob Health 2021; 6:e005671.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe